Product Description
Vaccine for Cigarette Smokers Who Are Motivated to Quit Smoking (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00736047)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for NIC-002](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Smoking Cessation|Tobacco Use Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2007-006741-40 | P2 |
Completed |
Tobacco Use Disorder |
2009-10-29 |
|
CNIC002A2201 | P2 |
Completed |
Tobacco Use Disorder|Smoking Cessation |
2009-10-01 |